Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Tax Provisions (2016 - 2026)

Ani Pharmaceuticals' Tax Provisions history spans 14 years, with the latest figure at $4.0 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 213.43% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.4 million, a 572.36% increase, with the full-year FY2025 number at $17.5 million, up 573.01% from a year prior.
  • Tax Provisions hit $4.0 million in Q4 2025 for Ani Pharmaceuticals, down from $7.2 million in the prior quarter.
  • Over the last five years, Tax Provisions for ANIP hit a ceiling of $7.2 million in Q3 2025 and a floor of -$7.3 million in Q3 2024.
  • Historically, Tax Provisions has averaged -$707263.2 across 5 years, with a median of -$996000.0 in 2023.
  • Biggest five-year swings in Tax Provisions: tumbled 57900.0% in 2022 and later soared 881.82% in 2024.
  • Tracing ANIP's Tax Provisions over 5 years: stood at -$6.8 million in 2021, then soared by 78.02% to -$1.5 million in 2022, then skyrocketed by 85.99% to -$208000.0 in 2023, then plummeted by 1575.96% to -$3.5 million in 2024, then soared by 213.43% to $4.0 million in 2025.
  • Business Quant data shows Tax Provisions for ANIP at $4.0 million in Q4 2025, $7.2 million in Q3 2025, and $2.0 million in Q2 2025.